Relevium Announces Record Sales From the Bioganix® Brand and Provides CBD Update
01 August 2019 - 11:41PM
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and
Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to
announce that the company hit a record high in monthly sales in the
month of July 2019 for its Bioganix® branded OTC business. The
Company’s revenues for the month increased by 46% from the previous
month, by 28% from same month last year and by 34% from the average
monthly revenues since 2017.
“This record high in monthly sales was driven
primarily by higher customer subscriptions, awareness optimization
in the UK and the successful and recent launch of PushPullSystemTM,
CardiaPro® and VisionPro®, a new series of high-end wellness
products.” stated Abis Hussain, Chief Marketing Officer at
Relevium.
CardiaPro® and VisionPro®The
Company launched two exclusive, evidence-based formulations of
Provinal® Omega 7 targeting heart health and vision care earlier
last month and the products continue to gain initial acceptance by
existing and new customers of the Bioganix® brand.
CardioPro® with Provinal® has been clinically
proven to support healthy LDL and HDL cholesterol, triglyceride,
and C-reactive protein (CRP) levels, four main biomarkers of heart.
VisionPro® is a complete eye health formulation that targets Dry
Eye Relief and blue light protection while supporting overall
vision health. Both products are expected to become available in
Canada and the UK by the second fiscal quarter of this year.
Push and Pull SystemTM Launched
in beta testing during the last quarter and aimed at the Hispanic
market in the US, the Push and Pull anti-aging system has performed
well in DTR and is gaining momentum through social media marketing.
The Company will continue to test distribution channels and to
optimize its online presence and social media outreach over the
next quarter when additional products are expected to be added to
the current offering. Additionally, the Company is expected to
launch the product to all US consumers by launching its English
presence on the web and on social media.
Update on Hemp Derived
ProductsIn the US and Europe, the health agencies have yet
to develop a clear framework for the sale of CBD products. In the
US, the FDA has prohibited the sale of CBD in supplements until it
declares its final position on the safety status of the cannabinoid
as an ingredient.
“The Company expects the current sales growth to
continue to trend upwards in the OTC business, but management is
taking a responsible approach in waiting for the final position by
the FDA on the use of CBD on supplements and skin care. We are
ready with a complete new line of exclusive nutraceuticals under
its Bioganix® brand and under LeefyLyfe which will comprise of
high-end organic broad spectrum hemp products and superfoods.”
stated Aurelio Useche, CEO at Relevium.
About Relevium TechnologiesRelevium is a
publicly-traded company that operates in the health and wellness
industry, including legal cannabis, with a primary focus on online
distribution. The principal business of the Company is the
identification, evaluation, acquisition and operation of brands and
businesses in the health and wellness markets and medical cannabis.
The Company pursues its business strategy through an acquisition
and partnership model in a holistic approach to encompass a wide
range of health and wellness consumer products. Relevium operates
through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including Walmart.com and
Amazon.com.
Biocannabix Health Corporation (BCX), based in
Montreal, Quebec, is a biopharma nutraceutical company focused on
delivering pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
StatementsThis release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian and United
States securities laws. All statements in this news release, other
than statements of historical facts, including statements regarding
future estimates, plans, objectives, assumptions or expectations of
future performance, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", or "would" occur.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek to rely on the
applicable safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release: Tel:
+1.888.528.8687Email: investors@releviumcorp.com Website:
www.releviumtechnologies.com
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024